Cost Concerns Impact National Reimbursement Strategy

BMI View: While news that Canadian authorities have tightened public drug plans will come as no surprise, reimbursement trends favouring cost-effective studies over clinical success stories should hint to drugmakers that governments are in no mood to buy new, slightly modified medicines when older variants and generic substitutes are just as effective.

To read the full article, please choose one of the following options: